Overview

Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) in the real world clinical setting in Japan.
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Tolvaptan